Last 12 months
Inside the activity.
0 purchase rows · 36 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 30 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2025 Filed Feb 19, 2025 02:43 UTC |
Hunt NimrataExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 6,320 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000024 · wk-form4_1739932982.xml · derivative · entry 7 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,320 Underlying: Common Stock · 6,320 shares Expires 2035-02-12 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC |
FENNELL GEORGEExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 816 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 8 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 816 Underlying: Common Stock · 816 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC |
FENNELL GEORGEExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 217 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 7 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217 Underlying: Common Stock · 217 shares Expires 2035-02-12 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC |
FENNELL GEORGEExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,415 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 6 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,415 Underlying: Common Stock · 3,415 shares Expires 2035-02-12 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC |
Erickson Michael GExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 734 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 9 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 734 Underlying: Common Stock · 734 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC |
Erickson Michael GExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 734 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 8 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 734 Underlying: Common Stock · 734 shares Expires not disclosed F3 · derivative.exercise_price: Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2026. F3 · derivative.exercise_date: Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2026. F3 · derivative.expiration_date: Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC |
Erickson Michael GExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 217 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 7 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217 Underlying: Common Stock · 217 shares Expires 2035-02-12 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC |
Erickson Michael GExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 6,320 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 6 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,320 Underlying: Common Stock · 6,320 shares Expires 2035-02-12 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 22:04 UTC |
Erickson Michael GExecutive Vice President
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,544 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0000874716-25-000008 · wk-form4_1739397872.xml · derivative · entry 2 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,544 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 1,544 shares of Issuer common stock that vested on February 14, 2021. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 22:04 UTC |
Erickson Michael GExecutive Vice President
|
Exercise / conversionCommon Stock | 1,544 | $67.85 | $104,760.40 |
DisclosureSEC source: 0000874716-25-000008 · wk-form4_1739397872.xml · nonDerivative · entry 1 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,836.3617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 22:00 UTC |
FENNELL GEORGEExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 9,986 | $0.00 Strike: $79.54 | $0.00 |
DisclosureSEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · derivative · entry 5 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,986 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant of option to buy 9,986 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 22:00 UTC |
FENNELL GEORGEExecutive Vice President
|
SaleCommon Stock | 9,986 | $462.53 | $4,618,861.53 |
DisclosureSEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · nonDerivative · entry 3 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,176 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $462.4501 to a high of $462.80 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 22:00 UTC |
FENNELL GEORGEExecutive Vice President
|
Exercise / conversionCommon Stock | 9,986 | $79.54 | $794,286.44 |
DisclosureSEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · nonDerivative · entry 2 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 22:03 UTC |
SZOSTAK M ANNEDirector
|
SaleCommon Stock | 3,000 | $465.95 | $1,397,835.00 |
DisclosureSEC source: 0000874716-25-000004 · wk-form4_1739224981.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 3,061 F1 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 22:00 UTC |
FENNELL GEORGEExecutive Vice President
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,256 | $0.00 Strike: $79.54 | $0.00 |
DisclosureSEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · derivative · entry 4 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,256 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant of option to buy 628 shares of Issuer common stock that vested in one installment on February 14, 2020, without giving effect to a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the 'Stock Split'). The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 22:00 UTC |
FENNELL GEORGEExecutive Vice President
|
Exercise / conversionCommon Stock | 1,256 | $79.54 | $99,902.24 |
DisclosureSEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · nonDerivative · entry 1 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2024 Filed Nov 29, 2024 22:00 UTC |
Vandebroek Sophie V.Director
|
SaleCommon Stock | 344 | $420.44 | $144,629.64 |
DisclosureSEC source: 0000874716-24-000144 · wk-form4_1732917601.xml · nonDerivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 905 Read SEC document |
| November 27, 2024 Filed Nov 29, 2024 22:00 UTC |
Vandebroek Sophie V.Director
|
GiftCommon Stock | 224 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000144 · wk-form4_1732917601.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,249 Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 20:20 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 112,605 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000132 · wk-form4_1725913212.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 122,605 Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 20:20 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 419,574 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000132 · wk-form4_1725913212.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Jonathan W. Ayers 2024 GRAT Disclosed balance after: 419,574 F2 · ownership.nature: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 20:20 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 302,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000132 · wk-form4_1725913212.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Jonathan W. Ayers 2022 GRAT Disclosed balance after: 0 F1 · ownership.nature: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 20:20 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 230,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000132 · wk-form4_1725913212.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,651 Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 20:18 UTC |
SZOSTAK M ANNEDirector
|
SaleCommon Stock | 500 | $469.37 | $234,686.15 |
DisclosureSEC source: 0000874716-24-000131 · wk-form4_1725913125.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The O'Hanian-Szostak Family Foundation Disclosed balance after: 0 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $468.98 to a high of $469.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation. Read SEC document |
| September 05, 2024 Filed Sep 9, 2024 20:18 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000131 · wk-form4_1725913125.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The O'Hanian-Szostak Family Foundation Disclosed balance after: 500 F2 · ownership.nature: The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation. Read SEC document |
| September 05, 2024 Filed Sep 9, 2024 20:18 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000131 · wk-form4_1725913125.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 6,061 F1 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:20 UTC |
Schreck MichaelExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-24-000127 · wk-form4_1725488990.xml · derivative · entry 3 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 164 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments beginning on September 1, 2021. F4 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments beginning on September 1, 2021. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments beginning on September 1, 2021. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:20 UTC |
Schreck MichaelExecutive Vice President
|
Tax withholdingCommon Stock | 48 | $481.33 | $23,103.84 |
DisclosureSEC source: 0000874716-24-000127 · wk-form4_1725488990.xml · nonDerivative · entry 2 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 913 F2 · price: Closing price of Issuer common stock on August 30, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:20 UTC |
Schreck MichaelExecutive Vice President
|
Exercise / conversionCommon Stock | 164 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000127 · wk-form4_1725488990.xml · nonDerivative · entry 1 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 11 shares purchased under the Issuer's Employee Stock Purchase Plan June 28, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:03 UTC |
Smith Martin AlexanderExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 18 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-24-000128 · wk-form4_1725489035.xml · derivative · entry 3 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18 Underlying: Common Stock · 18 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2022. F4 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2022. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2022. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:03 UTC |
Smith Martin AlexanderExecutive Vice President
|
Tax withholdingCommon Stock | 5 | $481.33 | $2,406.65 |
DisclosureSEC source: 0000874716-24-000128 · wk-form4_1725489035.xml · nonDerivative · entry 2 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509.95 F2 · price: Closing price of Issuer common stock on August 30, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:03 UTC |
Smith Martin AlexanderExecutive Vice President
|
Exercise / conversionCommon Stock | 18 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000128 · wk-form4_1725489035.xml · nonDerivative · entry 1 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 514.95 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 22 shares purchased under the Issuer's Employee Stock Purchase Plan on March 29, 2024 and June 28, 2024. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:01 UTC |
MCKEON BRIAN PEVP, CFO and Treasurer
|
Exercise / conversionRestricted Stock Unit · Derivative | 192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-24-000124 · wk-form4_1723064478.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. F3 · price: Not applicable F2 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. F2 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:01 UTC |
MCKEON BRIAN PEVP, CFO and Treasurer
|
Tax withholdingCommon Stock | 117 | $455.08 | $53,244.36 |
DisclosureSEC source: 0000874716-24-000124 · wk-form4_1723064478.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,931.5926 Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:01 UTC |
MCKEON BRIAN PEVP, CFO and Treasurer
|
Exercise / conversionCommon Stock | 192 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000124 · wk-form4_1723064478.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,048.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: (1) Includes a total of 22 shares purchased under the Issuer's Employee Stock Purchase Plan on March 29, 2024 and June 28, 2024. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:00 UTC |
MAZELSKY JONATHAN JAYDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 384 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-24-000122 · wk-form4_1723064403.xml · derivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 384 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. F2 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:00 UTC |
MAZELSKY JONATHAN JAYDirector · President and CEO
|
Tax withholdingCommon Stock | 170 | $455.08 | $77,363.60 |
DisclosureSEC source: 0000874716-24-000122 · wk-form4_1723064403.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,732.5926 Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:00 UTC |
MAZELSKY JONATHAN JAYDirector · President and CEO
|
Exercise / conversionCommon Stock | 384 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000122 · wk-form4_1723064403.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,902.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 22 shares purchased under the Issuer's Employee Stock Purchase Plan on March 29, 2024 and June 28, 2024. Read SEC document |
| May 17, 2024 Filed May 20, 2024 21:00 UTC |
Claflin Bruce L.Director
|
SaleCommon Stock | 200 | $540.80 | $108,160.00 |
DisclosureSEC source: 0000874716-24-000109 · wk-form4_1716238803.xml · nonDerivative · entry 1 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161 Read SEC document |
| May 08, 2024 Filed May 8, 2024 23:02 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 6,561 F1 · balance_after: Includes 1,604 shares of IDEXX Laboratories, Inc. common stock contributed by the reporting person to the Trust of M. Anne Szostak (as defined in note (2) below). F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ('Trust') and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document |
| May 08, 2024 Filed May 8, 2024 23:02 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC |
SZOSTAK M ANNEDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · derivative · entry 6 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC |
SZOSTAK M ANNEDirector
|
GrantRestricted Stock Unit · Derivative | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · derivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262 Underlying: Common Stock · 262 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC |
SZOSTAK M ANNEDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 609 | $0.00 Strike: $476.87 | $0.00 |
DisclosureSEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · derivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609 Underlying: Common Stock · 609 shares Expires 2034-05-05 F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC |
SZOSTAK M ANNEDirector
|
Exercise / conversionCommon Stock | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC |
Vandebroek Sophie V.Director
|
Exercise / conversionRestricted Stock Unit · Derivative | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000105 · wk-form4_1715209366.xml · derivative · entry 5 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event wa earlier. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event wa earlier. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event wa earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC |
Vandebroek Sophie V.Director
|
GrantRestricted Stock Unit · Derivative | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000105 · wk-form4_1715209366.xml · derivative · entry 4 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262 Underlying: Common Stock · 262 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC |
Vandebroek Sophie V.Director
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 609 | $0.00 Strike: $476.87 | $0.00 |
DisclosureSEC source: 0000874716-24-000105 · wk-form4_1715209366.xml · derivative · entry 3 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609 Underlying: Common Stock · 609 shares Expires 2034-05-05 F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC |
Vandebroek Sophie V.Director
|
Exercise / conversionCommon Stock | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000105 · wk-form4_1715209366.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC |
SAMAD SAMDirector
|
GrantDeferred Stock Unit · Derivative | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000103 · wk-form4_1715209335.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 863 Underlying: Common Stock · 262 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC |
SAMAD SAMDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 609 | $0.00 Strike: $476.87 | $0.00 |
DisclosureSEC source: 0000874716-24-000103 · wk-form4_1715209335.xml · derivative · entry 1 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609 Underlying: Common Stock · 609 shares Expires 2034-05-05 F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.